Credits: 1.0 contact hours (0.10 CEUs); 1 AMA PRA Category 1 Credit(s)™
David Calabrese, RPh, MHP, Assistant Clinical Professor, Northeastern University Bouve College of Pharmacy and Allied Health Sciences; Vice President, Clinical Operations, MedMetrics Health Partners, an SXC company
Educational Objectives
Upon completion of this educational activity, the participant should be able to:
Target Audience: The audience for this supplement consists of medical directors, pharmacy directors, and other managed care professionals who oversee the care of patients with CKD and cardiovascular disease.
David Calabrese, RPh, MHP, Assistant Clinical Professor, Northeastern University Bouve College of Pharmacy and Allied Health Sciences; Vice President, Clinical Operations, MedMetrics Health Partners, an SXC company
Educational Objectives
Upon completion of this educational activity, the participant should be able to:
- Identify the prevalence trends of chronic kidney disease (CKD) and evaluate the relationships between CKD and cardiovascular disease
- Evaluate evidence of various therapies in helping to improve cardiovascular outcomes in patients with CKD
- Review cost factors and cost-effectiveness of strategies used to improve outcomes in patients with CKD
Target Audience: The audience for this supplement consists of medical directors, pharmacy directors, and other managed care professionals who oversee the care of patients with CKD and cardiovascular disease.
0.8 contact hours (0.08 CEUs) per track; 0.75 AMA PRA Category 1 Credits™ per track
2.4 contact hours (0.24 CEUs) totoal; 2.25 AMA PRA Category 1 Credits™ total
Jeffrey D. Dunn, PharmD, MBA, Formulary and Contract Manager, SelectHealth, Inc.
James B. Groce III, PharmD, Professor of Pharmacy Practice, Campbell University School of Pharmacy
Albert L. Waldo, MD, The Walter H. Pritchard Professor of Cardiology, Case Western Reserve University
Educational Objectives
After completing this activity, participants should be able to:
Target Audience: This activity is intended for medical directors, pharmacy directors, and other managed care professionals who oversee the care of patients with thromboembolic disorders.
2.4 contact hours (0.24 CEUs) totoal; 2.25 AMA PRA Category 1 Credits™ total
Jeffrey D. Dunn, PharmD, MBA, Formulary and Contract Manager, SelectHealth, Inc.
James B. Groce III, PharmD, Professor of Pharmacy Practice, Campbell University School of Pharmacy
Albert L. Waldo, MD, The Walter H. Pritchard Professor of Cardiology, Case Western Reserve University
Educational Objectives
After completing this activity, participants should be able to:
- Describe evidence-based clinical practice guidelines for thromboprophylaxis in atrial fibrillation
- Evaluate recent advances in thromboprophylactic therapy including patient risks and benefits of emerging anticoagulants compared with standard treatments
- Outline managed care strategies that incorporate evolving treatment guidelines, therapies, and implementation processes to improve outcomes for patients with thromboembolic events
Target Audience: This activity is intended for medical directors, pharmacy directors, and other managed care professionals who oversee the care of patients with thromboembolic disorders.
Credits: 1.0 contact hours (0.10 CEUs); 1 AMA PRA Category 1 Credit(s)™
Ken Fujioka, MD, Nutrition and Metabolic Research Center, Scripps Clinic
Educational Objectives
After completing this activity, participants should be able to:
Target Audience: This activity is intended for medical directors, pharmacy directors, and other managed care professionals who oversee the care of patients with obesity.
Ken Fujioka, MD, Nutrition and Metabolic Research Center, Scripps Clinic
Educational Objectives
After completing this activity, participants should be able to:
- Recognize the health and economic burden associated with obesity
- Evaluate options available to manage obesity and the risks and benefits associated with each of them
- Identify strategies to help patients and providers improve the management of obesity
Target Audience: This activity is intended for medical directors, pharmacy directors, and other managed care professionals who oversee the care of patients with obesity.
Credits: 1.0 contact hours (0.10 CEUs); 1 AMA PRA Category 1 Credit(s)™
Jonathan D. Campbell, PhD, Department of Clinical Pharmacy, University of Colorado School of Pharmacy
Educational Objectives
After completing this activity, participants should be able to:
Target Audience: This activity is intended for medical directors, pharmacy directors, and other managed care professionals who oversee the care of patients with asthma.
Jonathan D. Campbell, PhD, Department of Clinical Pharmacy, University of Colorado School of Pharmacy
Educational Objectives
After completing this activity, participants should be able to:
- Describe the significance of unmet needs among people with asthma and elucidate contributing factors to poor asthma control
- Discuss the pharmacoeconomics of asthma therapy as it relates to clinical outcomes
- Examine new and emerging therapies for asthma and assess their role in the treatment of asthma
- Identify strategies for improving asthma control
Target Audience: This activity is intended for medical directors, pharmacy directors, and other managed care professionals who oversee the care of patients with asthma.
Credits: 1.0 contact hours (0.10 CEUs)
Laura T. Pizzi, PharmD, MPH, RPh, Associate Professor, Thomas Jefferson University School of Pharmacy
Dante A. Gravino, PharmD Candidate, Thomas Jefferson University School of Pharmacy of Pharmacy
Kangho Suh, PharmD Candidate, Rutgers University School of Pharmacy
Educational Objectives
After completing this activity, participants should be able to:
Target Audience: This activity is intended for pharmacists who wish to increase their knowledge of diabetes quality and who are involved in providing pharmacy benefit decisions for corporations.
Laura T. Pizzi, PharmD, MPH, RPh, Associate Professor, Thomas Jefferson University School of Pharmacy
Dante A. Gravino, PharmD Candidate, Thomas Jefferson University School of Pharmacy of Pharmacy
Kangho Suh, PharmD Candidate, Rutgers University School of Pharmacy
Educational Objectives
After completing this activity, participants should be able to:
- Discuss the relevance of diabetes as a target of healthcare quality improvement efforts
- Explain what US organizations are involved in diabetes quality improvement, and what types of measures have been implemented
- Discuss the history of and experiences in testing Pharmacy Quality Alliance measures pertaining to diabetes
- Recognize the potential future role of community pharmacists in improving the quality of diabetes care
Target Audience: This activity is intended for pharmacists who wish to increase their knowledge of diabetes quality and who are involved in providing pharmacy benefit decisions for corporations.
Credits: 1.0 contact hours (0.10 CEUs)
Michael Marlan Mohundro, PharmD, Director of Pharmacy, Our Lady of the Lake Regional Medical Center
Brice Labruzzo Mohundro, PharmD, Assistant Professor, University of Louisiana at Monroe College of Pharmacy—Baton Rouge Campus
Educational Objectives
After completing this activity, participants should be able to:
Target Audience: This activity is intended for pharmacists—in the community, health systems, or other environments—who treat patients with GI disorders, or any healthcare practitioners who are interested in the availability of new drugs to treat GI disorders.
Michael Marlan Mohundro, PharmD, Director of Pharmacy, Our Lady of the Lake Regional Medical Center
Brice Labruzzo Mohundro, PharmD, Assistant Professor, University of Louisiana at Monroe College of Pharmacy—Baton Rouge Campus
Educational Objectives
After completing this activity, participants should be able to:
- Identify and compare mechanisms of action, safety, tolerability, and efficacy profiles of emerging therapies for common gastrointestinal (GI) disorders
- Recognize the roles of emerging therapies for the treatment of specific GI disorders
Target Audience: This activity is intended for pharmacists—in the community, health systems, or other environments—who treat patients with GI disorders, or any healthcare practitioners who are interested in the availability of new drugs to treat GI disorders.
Credits: 1.0 contact hours (0.10 CEUs)
Anthony Elias, MD, Professor of Medicine, Medical Director, Breast Cancer and Sarcoma Programs, University of Colorado Cancer Center
Educational Objectives
After completing this activity, participants should be able to:
Target Audience: Pharmacy directors/administrators, clinical pharmacists practicing in managed care environments, and any other pharmacist practitioners involved in the care of patients diagnosed with cancer.
Anthony Elias, MD, Professor of Medicine, Medical Director, Breast Cancer and Sarcoma Programs, University of Colorado Cancer Center
Educational Objectives
After completing this activity, participants should be able to:
- List some of the major National Comprehensive Cancer Network (NCCN) practice guideline revisions presented at the 15th Annual Congress
- Identify select NCCN guideline revisions that may impact the course of treatment in a given case
- Discuss the use of patient characteristics to determine therapeutic management in select NCCN guideline revisions
Target Audience: Pharmacy directors/administrators, clinical pharmacists practicing in managed care environments, and any other pharmacist practitioners involved in the care of patients diagnosed with cancer.
